Aims: The present study was conducted to explore the effect of interleukin-33 (IL-33) on glycogen synthase kinase-3b (GSK-3b) activation involving Tau phosphorylation, a critical causative factor for Alzheimer's disease (AD). IL-33-induced Akt activation and GSK-3b inactivation were significantly inhibited by knocking-down myeloid differentiation factor 88 (MyD88), tumor necrosis factor receptor associated factor 6 (TRAF6), receptor-interacting protein (RIP), or phosphatidylinositol 3 kinase (PI3K). IL-33 neutralized amyloid b (Ab 1-42 )-induced Akt inactivation and GSK-3b activation. Significance: The results of the present study show that IL-33 inactivates GSK-3b through an ST2-independent MyD88/TRAF6/RIP/PI3K/Akt pathway and inhibits Ab 1-42 -induced GSK-3b activation. This suggests that IL-33 could restrain GSK3b-mediated Tau phosphorylation in AD.
Introduction
Interleukin-33 , that belongs to the IL-1 family [1] , is well-recognized to serve as a proinflammatory cytokine and a nuclear factor in a variety of cells [2, 3, 4] . Extracellular IL-33 transmits the signals through a heterodimeric receptor complex, comprising ST2 and interleukin-1 receptor accessory protein (IL-1RAcP) on the plasma membrane [5] . The receptor complex, activated by IL-33, recruits and activate myeloid differentiation factor 88 (MyD88), followed by activation of interleukin-1 receptor-associated kinase 4 (IRAK4) [1] . Then, IRAK4 phosphorylates IRAK1, to bind to and activate tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6). TRAF6 activates transforming growth factor-b (TGF-b)-activated kinase 1 (TAK1), followed by activation of mitogen-activated protein kinase (MAPK) cascades. The death receptor kinase receptor-interacting protein (RIP), alternatively, associates with TRAF6 and activates phosphatidylinositol 3 kinase (PI3K) [6, 7, 8] .
Accumulating evidence has pointed to the role of IL-33 in cognitive functions.
Exogenously applied IL-33 potentiates responses of a-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor, a major excitatory neurotransmitter receptor, expressed in Xenopus oocytes [9] . IL-33 deficiency suppresses Schaffer collateral/CA1 long-term potentiation (LTP), a cellular model of learning and memory, in the mouse hippocampus, which was neutralized by adding IL-33 [10] . These findings suggest that IL-33 is required for expression of LTP. In the water maze test, the acquisition latency in IL-33-deficient mice was significantly prolonged as compared with the latency in wild-type control mice [10] , suggesting the role of IL-33 in spatial learning and memory.
IL-33 exerts protective and toxic bidirectional actions in many organs, depending on its doses. IL-33 induces microglia-mediated neuroinflammation also [11] , while it exhibits neuroprotection effects [12, 13] . Moreover, IL-33 promotes microglial synapse engulfment and neural circuit development [14] .
Alzheimer's disease (AD) is characterized by extensive deposition of Ab called amyloid plaque and formation of neurofibrillary tangles (NFTs). When hyperphosphorylated, Tau detaches from the microtubules and forms insoluble fibrils, referred to as paired helical filaments (PHFs), and NFTs comprising aggregation of PHFs [15, 16] . Ab activates glycogen synthase kinase-3b (GSK-3b), to phosphorylate Tau, thereby initiating formation of PHFs and NFTs [17] . We have found that amyloid b 1-42 (Ab ) significantly reduces phosphorylation of GSK-3b at Ser9 and enhances phosphorylation of Tau at Ser202/Thr205/Ser396 in hippocampal slices from wild-type mice [18] . This indicates that Ab 1e42 induces GSK-3b activation and promotes Tau phosphorylation. We have also found that the levels of GSK-3b phosphorylation at Ser9 and Tau phosphorylation at Ser396 in the hippocampus from 5xFAD AD model mice at 6 months of age are significantly lower and higher, respectively, as compared with each of the levels in the hippocampus from wild-type mice [18] . It is shown that the levels of Ab 1e42 in the 5xFAD mouse brain increase in an age-dependent manner [19] . Moreover, we have found that Tau hyperphosphorylation in the hippocampus of 5xFAD mice precedes high GSK-3b activation [20] .
Collectively, these results further support the notion that Ab 1e42 triggers GSK-3b activation, thereby causing Tau hyperphosphorylation in the AD brain.
Higher levels of IL-33 are found in the AD brain cells and Ab upregulates IL-33 in cultured mouse astrocytes [21] . IL-33 reverses synaptic plasticity impairment and memory deficits in APP/PS1 mice, an animal model of AD [22] . IL-33 reduces soluble Ab levels and amyloid plaque deposition by promoting microglia-engaged phagocytosis of Ab [22] . Moreover, IL-33 may prevent conversion from mild cognitive impairment to AD [23] . Thus, IL-33 appears to play a role in AD.
The present study was conducted to understand the effects of IL-33 on the activity of GSK-3b involving Tau phosphorylation, a critical causative factor for AD. The results show that IL-33 inactivates GSK-3b through an ST2-independent MyD88/ TRAF6/RIP/PI3K/Akt pathway and suppresses Ab 1-42 -induced GSK-3b activation.
Materials and methods

Cell culture
PC-12 cells, obtained from RIKEN Cell Bank (Tsukuba, Japan), were cultured in DMEM with 10% (v/v) heat-inactivated FBS and 10% (v/v) heat-inactivated horse serum supplemented with penicillin (100 U/ml), and streptomycin (0.1 mg/mL), in a humidified atmosphere of 5% CO 2 and 95% air at 37 C. PC-12 cells were differentiated by treatment with nerve growth factor (100 ng/mL) for 5 days.
Protein knockdown
Protein knockdown was carried out by the method previously described [24] . Briefly, the siRNAs to silence the ST2-, MyD88-, IRAK4-, TRAF6-, TAK1-, RIP-, PI3K-, and 3-phosphoinositide-dependent protein kinase-1 (PDK1)-targeted genes and the negative control siRNA (NC siRNA) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Ambion (Carlsbad, CA, USA). In the graphs, each column represents the mean (AESEM) normalized signal intensity (n ¼ 8 independent
Western blot results). P values, unpaired t-test.
mM NaCl, 0.1% Tween20 and 20 mM Tris, pH 7.5) containing 5% (w/v) bovine serum albumin (Wako, Osaka, Japan) and reacted with antibodies against Akt (Cell Signaling, Beverly, MA, USA), phospho-Thr308-Akt (pT308-Akt) (Cell Signaling), phospho-Ser473-Akt (pS473-Akt) (Cell Signaling), GSK-3b (Cell Signaling), phospho-Ser9-GSK-3b (pS9-GSK-3b) (Cell Signaling), and phosphoTyr216-GSK-3b (pY216-GSK-3b) (BD Biosciences, San Jose, CA, USA), followed by a horseradish peroxidase-conjugated goat anti-mouse IgG antibody. The host species of all the primary antibodies used was mouse. Antibodies were used in 500e1000 times dilution. Immunoreactivity was detected with an ECL kit (GE Healthcare, Piscataway, NJ, USA) and visualized using a chemiluminescence detection system (GE Healthcare).
Activities of Akt and GSK-3b were analyzed by calculating the immunoreactive signal intensity for pT308-Akt and pS473-Akt relative to the signal intensity for Akt or the immunoreactive signal intensity for pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b.
Full Western blot images were not stored and therefore cannot be provided for any of the blots shown in the figures.
Statistical analysis
The statistical software STATA was purchased from Light Stone (Tokyo, Japan), and statistical analysis was carried out using unpaired t-test and analysis of variance (ANOVA) followed by a Bonferroni correction.
Results
IL-33 activates Akt and inactivates GSK-3b
My initial attempt was to assess the effect of IL-33 on the Akt and GSK-3b activities in differentiated PC-12 cells. Akt is activated by phosphorylation at Thr308 and/or Ser473. GSK-3b is inactivated by phosphorylation at Ser9 and activated by phosphorylation at Tyr216 [25] .
In my earlier study, IL-33 at a concentration of 1 ng/mL restored the suppression of Schaffer collateral/CA1 LTP in IL-33-deficient mice [10] . The same concentration of IL-33 (1 ng/mL), therefore, was used in the present study. IL-33 significantly enhanced pS473-Akt 30 min after treatment, although it had no effect on pT308-Akt (Fig. 2AeC) . Otherwise, IL-33 significantly enhanced pS9-GSK-3b 30 min after treatment, while pY216-GSK-3b was not affected (Fig. 2DeF ).
Collectively, these results indicate that IL-33 promotes Akt activation and GSK3b inactivation.
ST2 is not implicated in IL-33-induced Akt activation and GSK-3b inactivation
Subsequently, it was examined whether the effects of IL-33 on the Akt and GSK-3b activities are mediated by the IL-33 receptor ST2. IL-33 had no effect on pT308-Akt represents the mean (AESEM) signal intensity for pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments). P values shown in the graphs, ANOVA followed by a Bonferroni correction.
and pY216-GSK-3b in cells transfected with the NC siRNA or the ST2 siRNA (Fig. 3A ,B,D,F). IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA, but the effects were not affected by knocking-down ST2 (Fig. 3A,C 
,D,E). This indicates that IL-33 promotes Akt activation and GSK-3b
inactivation in an ST2-independent manner. pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments). P values shown in the graphs, ANOVA followed by a Bonferroni correction.
MyD88 is implicated in IL-33-induced Akt activation and GSK-3b inactivation
As mentioned before, MyD88 functions downstream the IL-33 receptor complex ST2/IL-1RAcP. IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA or the MyD88 siRNA (Fig. 4A,B,D,F) . However, IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA, and the effects were clearly inhibited by knocking-down MyD88 (Fig. 4A,C,D,E) . These results indicate that IL-33 promotes Akt activation and GSK-3b inactivation in an MyD88-dependent manner.
IRAK4 is not implicated in IL-33-induced Akt activation and GSK-3b inactivation
Since MyD88 activates IRAK4, to phosphorylate IRAK1, it was also evaluated whether IL-33 effects implicate IRAK4 activity. IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA or the IRAK4 siRNA (Fig. 5A ,B,D,F). Furthermore, IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA, but the effects were not affected by knocking-down IRAK4 (Fig. 5A ,C,D,E), indicating that IL-33 promotes Akt activation and GSK-3b inactivation in an IRAK4-independent manner.
TRAF6 is implicated in IL-33-induced Akt activation and GSK-3b inactivation
Phosphorylated IRAK1 binds to and activates TRAF6. Again, IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA or the TRAF6 siRNA (Fig. 6A,B,D,F) . Moreover, IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA. However, the effects were apparently inhibited by knocking-down TRAF6 (Fig. 6A,C,D,E) . This indicates that IL-33 promotes Akt activation and GSK-3b inactivation in a TRAF6-dependent manner.
TAK1 is not implicated in IL-33-induced Akt activation and GSK-3b inactivation
As previously described, TRAF6 activates TAK1 by forming an IRAK1/TRAF6/ TAK1/TAK binding protein 1 (TAB1)/TAB2/Ubc13/UeV1A complex, followed by activation of MAPK cascades [26] . Next, it was examined if IL-33 signaling involves TAK1. Once again, IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA or the TAK1 siRNA (Fig. 7A,B,D,F) . IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA, but the effects were not affected by knocking-down TAK1 signal intensity for pT308-Akt and pS473-Akt relative to the signal intensity for Akt (n ¼ 8 Western blot results from independent experiments). (E) (F) In the graphs, each column represents the mean (AESEM) signal intensity for pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments). P values shown in the graphs, AN-OVA followed by a Bonferroni correction. intensity for pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments. P values shown in the graphs, ANOVA followed by a Bonferroni correction. (Fig. 7A,C,D,E) . This indicates that IL-33 promotes Akt activation and GSK-3b inactivation in a TAK1-independent manner.
RIP is implicated in IL-33-induced Akt activation and GSK3b inactivation
It is possible that PI3K is activated through a RIP/TRAF6 pathway [6, 7, 8] . IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA or the RIP siRNA (Fig. 8A,B,D,F) . Furthermore, IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA. However, these effects were abolished by knocking-down RIP (Fig. 8A ,C,D,E),
indicating that IL-33 promotes Akt activation and GSK-3b inactivation in a RIPdependent manner. This also indicates that IL-33 could activate PI3K through a RIP/TRAF6 pathway.
PI3K is implicated in IL-33-induced Akt activation and GSK-3b inactivation
Akt is activated through a PI3K/PDK1 pathway. IL-33 had no effect on pT308-Akt and pY216-GSK-3b in cells transfected with the NC siRNA, the PI3K siRNA (Fig. 9A,B,D,F) , or the PDK1 siRNA (Fig. 10A,B,D,F) . IL-33 significantly enhanced pS473-Akt and pS9-GSK-3b in cells transfected with the NC siRNA, and the effects were abolished by knocking-down PI3K (Fig. 9A ,C,D,E), but not PDK1 (Fig. 10A,C,D,E) . This indicates that IL-33 promotes Akt activation and GSK-3b inactivation in a PI3K-dependent and PDK-1-independent manner.
IL-33 neutralizes Ab 1-42 -induced Akt-inactivation and GSK3b activation
My final attempt was to see the effect of IL-33 on Ab-induced GSK-3b activation. It is confirmed in the cell-free kinase assay that Akt induces GSK-3b phosphorylation at Ser9, i.e., Akt inactivates GSK-3b; conversely, inhibition of the Akt activity causes GSK-3b activation [18] . Ab 1-42 markedly reduced pS473-Akt and pS9-GSK-3b, although pT308-Akt and pY216-GSK-3b were not affected (Fig. 11AeF) . This implies that Ab 1-42 attenuates the Akt activity and enhances the GSK-3b activity. IL-33 significantly reversed Ab 1-42 -induced reduction of pS473-Akt and pS9-GSK-3b (Fig. 11A,C,D,E) . This indicates that IL-33 neutralizes Ab 1-42 -induced GSK-3b activation by enhancing the Akt activity.
Discussion
Akt is activated by phosphorylation at Thr308 and/or Ser473, and Akt inactivates GSK-3b by phosphorylating at Ser9. In the present study, it was observed that IL-33 enhanced pS473-Akt and pS9-GSK-3b in PC-12 cells. This indicates that IL-33
activates Akt, thereby phosphorylating and inactivating GSK-3b.
Extracellular IL-33 binds to ST2 and activates the heterodimeric receptor complex ST2/IL-1RAcP on the plasma membrane, followed by the sequential activation of (E) (F) In the graphs, each column represents the mean (AESEM) signal intensity for pS9-GSK-3b and pY216-GSK-3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments). P values shown in the graphs, ANOVA followed by a Bonferroni correction.
MyD88, IRAK4, TRAF6, TAK1, and MAPK [5] . Unexpectedly, the effects of IL-33 on the Akt and GSK-3b activities were not affected by knocking-down ST2, while the effects were clearly inhibited by knocking-down MyD88, a downstream target of ST2/IL-1RAcP. This indicates that IL-33 activates Akt and inactivates GSK-3b in an ST2-independent and MyD88-dependent manner. In the graphs, each column represents the mean (AESEM) signal intensity for pS9-GSK-3b and pY216-GSK3b relative to the signal intensity for GSK-3b (n ¼ 8 Western blot results from independent experiments). P values shown in the graphs, ANOVA followed by a Bonferroni correction.
Then, the question to address is how IL-33 activates MyD88 in an ST2-independent manner. In my earlier study, it was demonstrated that Schaffer collateral/CA1 LTP was suppressed in IL-33-or MyD88-deficient mice, but the LTP was not affected in ST2-deficient mice [10] . This, taken together with the present findings, suggests that IL-33 might activate MyD88 through a yet unidentified IL-33 receptor associating with IL-1RAcP, instead of ST2 (Fig. 12 ).
MyD88 triggers IRAK4-mediated IRAK1 phosphorylation, to activate TRAF6. IL-33-induced Akt activation and GSK-3b inactivation were significantly inhibited by Akt is activated through a major pathway along a receptor tyrosine kinase (RTK)/insulin receptor substrate 1 (IRS-1)/PI3K/PDK1/Akt axis, to inactivate GSK-3b by phosphorylating at Ser9. IL-33-induced Akt activation and GSK-3b inactivation were cancelled by knocking-down PI3K, but not PDK1. This indicates that IL-33
activates PI3K prior to activation of Akt. Several avenues of evidence have pointed to a pathway linked to IL-33-induced PI3K activation or Akt activation [26, 27, 28, 29] . How IL-33 activates PI3K or Akt, however, remained to be elucidated. IL-33 is shown to promote inflammation-induced lymphangiogenesis through an ST2-dependent TRAF6-mediated Akt activation pathway [30] . This pathway does not account for IL-33-induced Akt activation showed here, since the IL-33 effect was independent of ST2. On the other hand, TRAF6 is recognized to recruit RIP, to activate PI3K [6, 7, 8] . This raises the possibility that IL-33 could activate PI3K through a RIP/TRAF6 pathway. Expectedly, IL-33-induced Akt activation and GSK-3b inactivation were abolished by knocking-down RIP. Overall, the results of the present study lead to a conclusion that IL-33 activates Akt through an ST2- activates MyD88, regardless of ST2, followed by activation of the downstream effector TRAF6.
Then, TRAF6 recruits RIP, to activate PI3K and in turn, Akt. Akt inactivates GSK-3b by phosphorylating at Ser9. PM, plasma membrane.
independent MyD88/TRAF6/RIP/PI3K pathway, to phosphorylate and inactivate GSK-3b (Fig. 12 ).
Ab has been long thought to be a causative factor in AD. Recent interest highlights Ab activates Fyn, which activates GSK-3b by phosphorylating at Tyr216 [37, 38] . Ab, alternatively, inhibits PI3K/Akt, leading to activation of GSK-3b, to induce Tau phosphorylation [39, 40] . Soluble Ab oligomers inhibit insulin signaling relevant to Akt activation, thereby activating GSK-3b and increasing Tau phosphorylation [41] . Akt, PKCε, PKA, integrin-linked kinase (ILK), CaMKII, p90 ribosomal protein S6 kinase (p90RSK), and cGMP-dependent protein kinase 1 (PrkG1), on the other hand, inactivate GSK-3b by phosphorylating at Ser9 [18, 42, 43, 44, 45, 46] . In our earlier study, Ab 1e42 significantly reduced phosphorylation of GSK-3b at Ser9 in mouse hippocampal slices [18] , indicating that Ab 1e42 activates GSK-3b. It is recognized that b-catenin is a substrate of GSK-3b [47] . Ab 1e42 significantly enhanced phosphorylation of b-catenin at Ser33/Ser37/Thr41 in mouse hippocampal slices, and the effect was restrained by DCP-LA, a selective PKCε activator that acts as a potential inhibitor of GSK-3b [18] , providing convincing evidence for Ab 1e42 -induced GSK-3b activation. Moreover, Ab 1e42 significantly enhanced phosphorylation of Tau at Ser202/Thr205/Ser396 in mouse hippocampal slices, and the effect was also clearly inhibited by DCP-LA [18] , indicating that Ab 1e42 promotes Tau phosphorylation by activating GSK-3b. Notably, DCP-LA suppressed GSK-3b activation and Tau phosphorylation in the 5xFAD mouse hippocampus and ameliorated spatial learning and memory impairment in 5xFAD mice. Like DCP-LA, IL-33 neutralized Ab 1-42 -induced GSK-3b activation. This raises the possibility that IL-33 could prevent GSK-3b-mediated Tau phosphorylation in AD. IL-33, thus, could become a promising target in the development of therapeutic drugs of tauopathy including AD.
In conclusion, the results of the present study show that IL-33 suppresses GSK-3b activation through an ST2-independent MyD88/TRAF6/RIP/PI3K/Akt pathway and neutralizes Ab 1-42 -induced Akt inactivation and GSK-3b activation. This may represent fresh insight into the IL-33 signal transduction pathways relevant to prevention of Tau phosphorylation.
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